Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRedICT-TOPIC: Predicting response to topical imiquimod in cervical HSIL
NL-OMON51652Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Jun 2022
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (3 arms), sponsored by Catharina Ziekenhuis. Primary endpoints: Association of stromal immune infiltrates with complete response, Validation of hot signature association and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NL-OMON51652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51652.